Skip to content

Clinical trials

Fanconi Anemia trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Fanconi Anemia Phase: Not applicable Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20041
20071
20091
20101
20111
20222
20231
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed8
Terminated3
Withdrawn2
Active, not recruiting1
Recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fairview University Medical Center2
Masonic Cancer Center, University of Minnesota2
Assistance Publique - Hôpitaux de Paris1
Children's Hospital Medical Center, Cincinnati1
Emory University1
M.D. Anderson Cancer Center1
Memorial Sloan Kettering Cancer Center1
National Center for Research Resources (NCRR)1
National Heart, Lung, and Blood Institute (NHLBI)1
Neena Kapoor, M.D.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Fanconi Anemia15
Anemia, Aplastic5
Anemia, Diamond-Blackfan3
Hematologic Diseases3
Leukemia, Myeloid, Acute3
Precursor Cell Lymphoblastic Leukemia-Lymphoma3
Rare Diseases3
Burkitt Lymphoma2
Congenital Abnormalities2
Dendritic Cell Sarcoma, Interdigitating2

Trials

Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.